- Home
- LAW vs GALT Comparison
LAW vs GALT Comparison
Compare LAW & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- GALT
- Stock Information
- Founded
- LAW 2013
- GALT 2000
- Country
- LAW United States
- GALT United States
- Employees
- LAW N/A
- GALT N/A
- Industry
- LAW Computer Software: Prepackaged Software
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- LAW Technology
- GALT Health Care
- Exchange
- LAW Nasdaq
- GALT Nasdaq
- Market Cap
- LAW 249.3M
- GALT 232.3M
- IPO Year
- LAW 2021
- GALT N/A
- Fundamental
- Price
- LAW $6.21
- GALT $4.74
- Analyst Decision
- LAW Buy
- GALT Strong Buy
- Analyst Count
- LAW 2
- GALT 3
- Target Price
- LAW $6.75
- GALT $6.00
- AVG Volume (30 Days)
- LAW 151.3K
- GALT 371.9K
- Earning Date
- LAW 11-05-2025
- GALT 11-12-2025
- Dividend Yield
- LAW N/A
- GALT N/A
- EPS Growth
- LAW N/A
- GALT N/A
- EPS
- LAW N/A
- GALT N/A
- Revenue
- LAW $148,024,000.00
- GALT N/A
- Revenue This Year
- LAW $7.13
- GALT N/A
- Revenue Next Year
- LAW $6.25
- GALT N/A
- P/E Ratio
- LAW N/A
- GALT N/A
- Revenue Growth
- LAW 4.05
- GALT N/A
- 52 Week Low
- LAW $3.31
- GALT $0.73
- 52 Week High
- LAW $6.81
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- LAW 51.09
- GALT 63.90
- Support Level
- LAW $5.90
- GALT $4.10
- Resistance Level
- LAW $6.54
- GALT $5.06
- Average True Range (ATR)
- LAW 0.25
- GALT 0.28
- MACD
- LAW -0.11
- GALT -0.02
- Stochastic Oscillator
- LAW 8.24
- GALT 72.92
About LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.